Neoleukin appoints interim CEO and CFO after Drachman resignation; CMO Patel departs

Neurogene Inc.

Donna Cochener appointed Interim CEO; Sean Smith appointed Interim CFO, effective March 31, 2023.
Dr. Jonathan Drachman resigned as President, CEO and director, effective March 31, 2023 (previously announced March 6).
Cochener receives base salary $450,000; Smith $410,000; annual bonuses and retention bonuses up to $219,375 and $159,167 respectively.
CMO Dr. Priti Patel separated; receives 9 months salary continuation, healthcare, and accelerated vesting of 100,000 options.
Interim officers' severance: 9 months salary plus COBRA; enhanced 15 months lump sum on change of control.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Donna M. Cochener

Interim Chief Executive Officer

NGNE · Neurogene Inc.

Effective: 2023-03-31
Filed: April 3, 2023, 7:59 PM ET

the Board of Directors (the "Board") of Neoleukin Therapeutics, Inc. (the "Company") appointed (a) Donna M. Cochener as the Company’s Interim Chief Executive Officer

Departed

Jonathan Drachman

President, Chief Executive Officer, principal executive and financial officer and director

NGNE · Neurogene Inc.

Effective: 2023-03-31
Successor: Donna M. Cochener
Filed: April 3, 2023, 7:59 PM ET

Dr. Jonathan Drachman, M.D.'s resignation from his role as President, Chief Executive Officer, principal executive and financial officer and director of the Company as of the Effective Date

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Donna M. Cochener was appointed as Interim Chief Executive Officer at Neurogene Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

the Board of Directors (the "Board") of Neoleukin Therapeutics, Inc. (the "Company") appointed (a) Donna M. Cochener as the Company’s Interim Chief Executive Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jonathan Drachman resigned as President, Chief Executive Officer, principal executive and financial officer and director at Neurogene Inc..

Action: resigned
Role: President, Chief Executive Officer, principal executive and financial officer and director

Exact text from the filing

Dr. Jonathan Drachman, M.D.'s resignation from his role as President, Chief Executive Officer, principal executive and financial officer and director of the Company as of the Effective Date

View on SEC.gov

Neurogene Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-010410

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.